File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Metaplastic breast cancer is heterogeneous; treatment should be personalized

TitleMetaplastic breast cancer is heterogeneous; treatment should be personalized
Authors
Issue Date2021
PublisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2559
Citation
The 45th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology, Virtual Meeting, 22-24 April 2021. In Histopathology, 2021, v. 79 n. Suppl. S1, p. 11 How to Cite?
AbstractBackground: Metaplastic breast cancers are uncommon, predominantly triple-negative with generally poor outcomes and consist of various combinations and permutations of squamous carcinoma and sarcomatous components. Aims: To learn from our population of metaplastic carcinomas the relevance of predictive biomarkers. Methods: The anatomic pathology database was searched for metaplastic carcinoma. H&E and IHC slides were reviewed and clinical information gleaned from the HIS. Results & Conclusions: There were 2,804 breast cancer diagnosis and 1,720 HER2 tests in a 5-year period. Six patients were diagnosed with metaplastic carcinoma. Two patients had squamous carcinoma (pure, which is HER2-overexpressed/ER-/PR-, 1 case; and PR-weak/ER-/HER2-negative, with residual invasive breast carcinoma, no special type [IBCNST]). One had triple-negative spindle cell sarcoma with residual ER-weak IBCNST. The rest have heterologous sarcoma (ER-negative osteosarcoma, 1 case; triple negative chondrosarcoma with squamous carcinoma or IBCNST, 2 cases). The single patient with a huge HER2-overexpressed squamous metaplastic carcinoma (pT3N2)showed partial pathological response to neoadjuvant Herceptin therapy and went on to survive with disease for at least 4 years. We conclude that metaplastic carcinoma is rare in our population, is heterogeneous in composition and expression of predictive markers, and are mostly high-grade in histology, but have meaningful survival if targeted therapy can be offered.
Persistent Identifierhttp://hdl.handle.net/10722/305760
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 1.392

 

DC FieldValueLanguage
dc.contributor.authorTong, SW-
dc.contributor.authorSun, S-
dc.contributor.authorLiu, JR-
dc.date.accessioned2021-10-20T10:13:56Z-
dc.date.available2021-10-20T10:13:56Z-
dc.date.issued2021-
dc.identifier.citationThe 45th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology, Virtual Meeting, 22-24 April 2021. In Histopathology, 2021, v. 79 n. Suppl. S1, p. 11-
dc.identifier.issn0309-0167-
dc.identifier.urihttp://hdl.handle.net/10722/305760-
dc.description.abstractBackground: Metaplastic breast cancers are uncommon, predominantly triple-negative with generally poor outcomes and consist of various combinations and permutations of squamous carcinoma and sarcomatous components. Aims: To learn from our population of metaplastic carcinomas the relevance of predictive biomarkers. Methods: The anatomic pathology database was searched for metaplastic carcinoma. H&E and IHC slides were reviewed and clinical information gleaned from the HIS. Results & Conclusions: There were 2,804 breast cancer diagnosis and 1,720 HER2 tests in a 5-year period. Six patients were diagnosed with metaplastic carcinoma. Two patients had squamous carcinoma (pure, which is HER2-overexpressed/ER-/PR-, 1 case; and PR-weak/ER-/HER2-negative, with residual invasive breast carcinoma, no special type [IBCNST]). One had triple-negative spindle cell sarcoma with residual ER-weak IBCNST. The rest have heterologous sarcoma (ER-negative osteosarcoma, 1 case; triple negative chondrosarcoma with squamous carcinoma or IBCNST, 2 cases). The single patient with a huge HER2-overexpressed squamous metaplastic carcinoma (pT3N2)showed partial pathological response to neoadjuvant Herceptin therapy and went on to survive with disease for at least 4 years. We conclude that metaplastic carcinoma is rare in our population, is heterogeneous in composition and expression of predictive markers, and are mostly high-grade in histology, but have meaningful survival if targeted therapy can be offered.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2559-
dc.relation.ispartofHistopathology-
dc.relation.ispartofThe 45th Annual Scientific Meeting of the Australasian Division of the International Academy of Pathology-
dc.titleMetaplastic breast cancer is heterogeneous; treatment should be personalized-
dc.typeConference_Paper-
dc.identifier.emailTong, SW: ttongmd@hku.hk-
dc.description.natureabstract-
dc.identifier.doi10.1111/his.14477-
dc.identifier.hkuros326630-
dc.identifier.volume79-
dc.identifier.issueSuppl. S1-
dc.identifier.spage11-
dc.identifier.epage11-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats